

Supplemental materials and methods

Bacterial strains and plasmids. *Escherichia coli* strain DH5 α (1) containing conjugative plasmid pJC01 was used as donor strain and streptomycin-resistant derivative *E. coli* BL21 (DE3) (2) was used as recipient strain expressing T7 RNA polymerase in HTC assay. *E. coli* DH5 α (1) containing different conjugative and mobilizable plasmids (Table S1) and a rifampicin-resistant derivative of *E. coli* MDS52 (3) were used as donor and recipient strains respectively in plate-conjugation assays. *Salmonella enterica* Serovar *typhimurium* SV4522 was used as donor strain of a kanamycin-resistant derivative of pSLT plasmid (4). *Acinetobacter baumannii* ATCC 19606 (provided by Hospital de Valdecilla, Spain), *Vibrio cholera* N16961 (provided by Didier Mazel, Institut Pasteur, France), *Salmonella enterica* Serovar *typhimurium* SV4939 (provided by Dr. J. Casadesús, Universidad de Sevilla, Spain), *Agrobacterium tumefaciens* C58 (provided by Dr D. Pérez-Mendoza, Estación Experimental del Zaidín, Spain) and *Pseudomonas putida* KT2440 (provided by Dr. F. Rojo, Centro Nacional de Biotecnología, Spain) were used as donor strains of R388. Nalidixic and rifampicin-resistant derivatives of *E. coli* BW27783 (5) were used as donor (containing R1drd19 plasmid) and recipient strains respectively in liquid matings. *E. coli* DH5 α (1) containing pHP161 (6) and pKM101 Δ MOB (7) was used as donor strain to combine *oriT*-MOB of R388 and MPF apparatus of pKM101, respectively.

Reagents. When appropriate, antibiotics (Apollo) were added at the following concentrations: ampicillin sodium salt (Ap; 100 μ g/ml), chloramphenicol (Cm; 25 μ g/ml), nalidixic acid (Nx; 20 μ g/ml), rifampicin (Rif; 50 μ g/ml), streptomycin (Sm;

300 µg/ml), tetracycline (Tc; 10 µg/ml) and trimethoprim (Tp; 10 µg/ml). DMSO (Sigma-Aldrich) was used as solvent and IPTG (Sigma-Aldrich) as T7 RNA polymerase inductor. Bacterial cultures were set up in LB-broth and LB-agar (Pronadisa). M9 broth (Sigma-Aldrich) were used to resuspend bacteria after mating and perform serial dilutions.

Construction of pJC01. The *Xba*I fragment of plasmid pUA66 (8) encoding the GFPmut2 protein (9) was inserted into the *Xba*I site of plasmid pET3a (Novagen) to obtain pETGFP3, where the *gfpmut2* gene is under the control of the T7 ϕ 10 promoter. Then, the chloramphenicol resistance gene (*Cm^r*) from pSB1C3 (<http://parts.igem.org/Part:pSB1C3>) was amplified by PCR using the primers *Cm^r* sense (CGTAAGATCTTCCAACCTTTCACCATAATG) and *Cm^r* antisense (AGCTAGATCTCAAATTACGCCCCGCCCTG), which introduce *Bgl*II sites at both ends of the amplicon. The *Cm^r* fragment was digested with *Bgl*II and inserted in the same site of pETGFP3 (flanking the *gfpmut2* gene in a divergent orientation) to obtain the construct pETGFP-*Cm6*. This plasmid was used as template to amplify the region containing the adjacent (and divergent) genes *gfpmut2* and *Cm^r* by PCR using the primers Sense-*Eco*RI (CAGCGAATTCAGCTTCCTTTTCGGCTTTG) and Antisense-*Sac*I (AGTGGCGAGCTCGATCTTCCCCATCGGTG). Subsequently, the amplified *gfpmut2-Cm^r* cassette was digested with *Eco*RI and *Sac*I enzymes and inserted into the conjugative plasmid R388 (10), previously digested with the same enzymes, to obtain the final construction pJC01.

References

1. Grant, S. G., Jessee, J., Bloom, F. R., Hanahan, D. 1990. Differential plasmid rescue from transgenic mouse DNAs into *Escherichia coli* methylation-restriction mutants. *Proc. Natl. Acad. Sci. U. S. A.* 87:4645-4649.
2. Studier, F. W., Moffatt, B. A. 1986. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. *J. Mol. Biol.* 189:113-130.
3. Posfai, G., Plunkett, G., 3rd, Feher, T., Frisch, D., Keil, G. M., Umenhoffer, K., Kolisnychenko, V., Stahl, B., Sharma, S. S., de Arruda, M., Burland, V., Harcum, S. W., Blattner, F. R. 2006. Emergent properties of reduced-genome *Escherichia coli*. *Science* 312:1044-1046.
4. Camacho, E. M., Casadesus, J. 2002. Conjugal transfer of the virulence plasmid of *Salmonella enterica* is regulated by the leucine-responsive regulatory protein and DNA adenine methylation. *Mol. Microbiol.* 44:1589-1598.
5. Khlebnikov, A., Skaug, T., Keasling, J. D. 2002. Modulation of gene expression from the arabinose-inducible *araBAD* promoter. *Journal of industrial microbiology & biotechnology* 29:34-37.
6. Fernandez-Gonzalez, E., de Paz, H. D., Alperi, A., Agundez, L., Faustmann, M., Sangari, F. J., Dehio, C., Llosa, M. 2011. Transfer of R388 derivatives by

a pathogenesis-associated type IV secretion system into both bacteria and human cells. *J. Bacteriol.* 193:6257-6265.

7. Draper, O., Cesar, C. E., Machon, C., de la Cruz, F., Llosa, M. 2005. Site-specific recombinase and integrase activities of a conjugative relaxase in recipient cells. *Proc. Natl. Acad. Sci. U. S. A.* 102:16385-16390.
8. Zaslaver, A., Bren, A., Ronen, M., Itzkovitz, S., Kikoin, I., Shavit, S., Liebermeister, W., Surette, M. G., Alon, U. 2006. A comprehensive library of fluorescent transcriptional reporters for *Escherichia coli*. *Nature methods* 3:623-628.
9. Cormack, B. P., Valdivia, R. H., Falkow, S. 1996. FACS-optimized mutants of the green fluorescent protein (GFP). *Gene* 173:33-38.
10. Datta, N., Hedges, R. W. 1972. Trimethoprim resistance conferred by W plasmids in *Enterobacteriaceae*. *J. Gen. Microbiol.* 72:349-355.